JNJ-88260237

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-88260237, covering 2025-03-30 to 2025-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants [Phase 1]